Home/ Stocks/ PHIO

Phio Pharmaceuticals Corp. Common Stock

PHIO XNAS

$1.07 -0.04 (-3.60%) ▼ 15-min delayed

Open

$1.15

High

$1.15

Low

$1.04

Volume

324.3K

Market Cap

$12.43M

About Phio Pharmaceuticals Corp. Common Stock

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 6 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-4,003,000	$-0.34
FY 2025	$0	$-8,698,000	$-1.45
Q3 2025	$0	$-2,392,000	$-0.44
Q2 2025	$0	$-2,166,000	$-0.45

Related Market News

No specific coverage for PHIO yet. Check out our latest market news or earnings calendar.

Get PHIO Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Phio Pharmaceuticals Corp. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.